ArticleThe Journal of clinical investigation2018
Imaging activated T cells predicts response to cancer vaccines.
Article in The Journal of clinical investigation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Application of immunoPET imaging to enhance head and neck squamous cell carcinoma clinical management.Frontiers in oncology · 2025Pooled it
- Integrated imaging and molecular analysis to decipher tumor microenvironment in the era of immunotherapy.Seminars in cancer biology · 2022Pooled it
- Challenges in tracer development for tumor microenvironment (TME) imaging.European journal of nuclear medicine and molecular imaging · 2026Review
- IFN-γ PET imaging stratifies and predicts response to CD137 agonism in a syngeneic colorectal tumor model.Journal for immunotherapy of cancer · 2026Article
- Granzyme B PET/CT predicts chemo-immunotherapy outcomes in microsatellite stable gastric cancers.European journal of nuclear medicine and molecular imaging · 2026Article
- Metabolic [¹⁸F]F-AraG PET imaging of T Cell activation: a functional complement to cell-specific immune tracers.EJNMMI research · 2026Review
- Emerging ImmunoPET probes for precision cancer immunotherapy: molecular targets and translational applications.Frontiers in oncology · 2026Review
- Imaging the fate of CAR-T cellsFrontiers in immunology · 2026Review
- The application and prospect of granzyme B-targeted PET imaging in cancer immunotherapy.Journal of translational medicine · 2025Review
- Development of a novelJournal for immunotherapy of cancer · 2025Article
- Monitoring T-Cell Activation in the Tumor Microenvironment by PET Imaging of the Chemokine CXCL9.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Advancing In Vivo Detection of T-Cell Function: Development and Preclinical Evaluation ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Harnessing Biomarker Activatable Probes for Early Stratification and Timely Assessment of Therapeutic Efficacy in Cancer.Exploration (Beijing, China) · 2025Review
- Exploring molecular imaging to investigate immune checkpoint inhibitor-related toxicity.Journal for immunotherapy of cancer · 2025Review
- Positron Emission Tomography Imaging of the Adaptive Immune System in Cardiovascular Diseases.Chemical & biomedical imaging · 2025Review
- Radiopharmaceuticals and their applications in medicine.Signal transduction and targeted therapy · 2025Review
- Imaging antigen processing and presentation in cancer.Immunotherapy advances · 2025Review
- [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Validation of the C-X-C chemokine receptor 3 (CXCR3) as a target for PET imaging of T cell activation.EJNMMI research · 2024Article
- Peptide-based PET tracer targeting LAG-3 for evaluating the efficacy of immunotherapy in melanoma.Journal for immunotherapy of cancer · 2024Article
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
In situ cancer vaccines are under active clinical investigation, given their reported ability to eradicate both local and disseminated malignancies. Intratumoral vaccine administration is thought to activate a T cell-mediated immune response, which begins in the treated tumor and cascades systemically. In this study, we describe a PET tracer (64Cu-DOTA-AbOX40) that enabled noninvasive and longitudinal imaging of OX40, a cell-surface marker of T cell activation. We report the spatiotemporal dynamics of T cell activation following in situ vaccination with CpG oligodeoxynucleotide in a dual tumor-bearing mouse model. We demonstrate that OX40 imaging was able to predict tumor responses on day 9 after treatment on the basis of tumor tracer uptake on day 2, with greater accuracy than both anatomical and blood-based measurements. These studies provide key insights into global T cell activation following local CpG treatment and indicate that 64Cu-DOTA-AbOX40 is a promising candidate for monitoring clinical cancer immunotherapy strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.